TY - JOUR
T1 - Type IV Hyperlipoproteinemia
T2 - Clofibrate Without Dietary Therapy
AU - Zelis, Robert
AU - Amsterdam, Ezra A.
AU - Spann, James F.
AU - Mason, Dean T.
PY - 1972/10/16
Y1 - 1972/10/16
N2 - Since weight reduction, the cornerstone of treatment in type IV hyperlipoproteinemia, has poor patient acceptance, clofibrate (2 gm/day) was evaluated in a double-blind study prior to dietary therapy in 12 patients. Mean plasma triglyceride levels fell with clofibrate (429 mg/100 ml to 255 mg/100 ml) but not with placebo (565 mg/100 ml). In most patients, cholesterol levels were unchanged. Although clofibrate alone may be effective in certain type IV patients if both cholesterol and triglyceride levels are substantially reduced, it is no substitute for adequate dietary therapy.
AB - Since weight reduction, the cornerstone of treatment in type IV hyperlipoproteinemia, has poor patient acceptance, clofibrate (2 gm/day) was evaluated in a double-blind study prior to dietary therapy in 12 patients. Mean plasma triglyceride levels fell with clofibrate (429 mg/100 ml to 255 mg/100 ml) but not with placebo (565 mg/100 ml). In most patients, cholesterol levels were unchanged. Although clofibrate alone may be effective in certain type IV patients if both cholesterol and triglyceride levels are substantially reduced, it is no substitute for adequate dietary therapy.
UR - http://www.scopus.com/inward/record.url?scp=0015512894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0015512894&partnerID=8YFLogxK
U2 - 10.1001/jama.1972.03210030048013
DO - 10.1001/jama.1972.03210030048013
M3 - Article
C2 - 4566727
AN - SCOPUS:0015512894
SN - 0002-9955
VL - 222
SP - 326
EP - 328
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 3
ER -